Skip to main content
Publications
Anthony MS, Djebarri L, Beachler DC, Aroda VR, Calingaert B, Pan C, Crowe C, Lanes S, Rothman KJ, Saltus CW, Berreghis S, Parlett LE, Bocage C, Walsh KE, Juhaeri J, Johannes C. Risk of anaphylaxis among new users of glucagon-like peptide-1 receptor agonists (GLP-1 RAs). Poster presented at the American Diabetes Association's 83rd Scientific Sessions; June 23, 2023. San Diego, CA. [abstract] Diabetes. 2023 Jun 20; 72(supplement_1):846-P. doi: 10.2337/db23-846-P
Martin-Richard M, Gallego R, Pericay C, Garcia Foncillas JG, Queralt B, Casado E, Barriuso J, Iranzo V, Juez I, Visa L, Saigi E, Barnadas A, Garcia-Albeniz X, Maurel J. Multicenter phase II study of oxaliplatin and sorafenib in advanced gastric adenocarcinoma after failure of cisplatin and fluoropyrimidine treatment. A GEMCAD study. Invest New Drugs. 2013 Dec;31(6):1573-9.